Daxor
About: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Employees: 750
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
7% more capital invested
Capital invested by funds: $757K [Q3] → $811K (+$54.7K) [Q4]
0.36% more ownership
Funds ownership: 1.8% [Q3] → 2.16% (+0.36%) [Q4]
0% more funds holding
Funds holding: 9 [Q3] → 9 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for DXR.
Financial journalist opinion
Based on 13 articles about DXR published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript
Daxor Corporation (NASDAQ:DXR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024.
Neutral
GlobeNewsWire
1 week ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023.
Neutral
GlobeNewsWire
1 week ago
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments.
Neutral
GlobeNewsWire
1 week ago
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw.
Neutral
GlobeNewsWire
1 week ago
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
Neutral
GlobeNewsWire
1 week ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2023 versus $7.08 for the comparable period in 2023.
Neutral
GlobeNewsWire
1 week ago
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into a leading Midwest healthcare facility. This 735-bed medical campus will integrate Daxor's blood volume analysis (BVA) testing into its outpatient care, enhancing precision in fluid management and patient outcomes.
Neutral
GlobeNewsWire
2 weeks ago
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Leading Academic Health System Adopts Daxor's Innovative Blood Volume Measurement Capabilities at Two Key Facilities Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey's largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to maintain this accelerated sales trajectory throughout 2025.
Neutral
GlobeNewsWire
3 weeks ago
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces groundbreaking new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference (THT). Held from February 11-13, 2025, at the Omni Boston Hotel at the Seaport, the event gathered leading experts in heart failure innovation.
Neutral
Business Wire
3 weeks ago
TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team
TEMPE, Ariz.--(BUSINESS WIRE)--TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intelligence capabilities and scales to meet the needs of hospital systems, educational institutions and other healthcare organizations nationwide. Walter D. Conwell, MD, MBA, now serves as president. Previously serving as chief diversity and inclusion officer and associate dean for faculty development at t.
Charts implemented using Lightweight Charts™